While GE HealthCare Technologies has notably underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Baxter has notably underperformed the Medical Devices industry over the past year, and analysts are cautious about the stock’s prospects.
Zimmer Biomet Holdings stock has lagged other medical device stocks over the past year, while analysts are neutral about its prospects.
Although Thermo Fisher Scientific stock has declined over the past year, it has slightly outperformed other medical device stocks, and analysts remain highly bullish about its prospects.
As ResMed has outpaced the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Stryker has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
Zimmer Biomet has trailed the broader market over the past year, and it continues to face skeptical sentiment from analysts regarding its near- to medium-term growth outlook.
While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Medical device stocks have started 2026 looking weak. But there are signs of life if you know where to look.
GE HealthCare Technologies has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.